Holen Sie sich die Stockscreener-App
2.11
1.86%
-0.04
Vorhandelsmarkt:
2.09
-0.02
-0.95%
Schlusskurs vom Vortag:
$2.15
Offen:
$1.99
24-Stunden-Volumen:
914.64K
Relative Volume:
0.24
Marktkapitalisierung:
$4.19M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.22M
KGV:
-0.0772
EPS:
-27.3467
Netto-Cashflow:
$-8.01M
1W Leistung:
-16.27%
1M Leistung:
+15.93%
6M Leistung:
-63.87%
1J Leistung:
-87.07%
1-Tages-Spanne:
$1.86
$2.14
1-Wochen-Bereich:
$1.86
$2.64
52-Wochen-Spanne:
$1.71
$17.64
Enveric Biosciences Inc Stock (ENVB) Company Profile
Firmenname
Enveric Biosciences Inc
Sektor
Branche
Telefon
(617) 444-8400
Adresse
245 FIRST STREET RIVERVIEW II 18TH FLOOR, CAMBRIDGE
Compare ENVB vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ENVB
Enveric Biosciences Inc
|
2.11 | 4.27M | 0 | -8.22M | -8.01M | -27.35 |
VRTX
Vertex Pharmaceuticals Inc
|
434.31 | 110.81B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
630.30 | 66.02B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
797.77 | 48.27B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
294.30 | 38.22B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
147.30 | 30.69B | 742.00K | -1.37B | -1.07B | -7.0731 |
Enveric Biosciences Inc Aktie (ENVB) Neueste Nachrichten
Enveric Biosciences Reports Positive Preclinical Results from Phototoxicity Analysis for Lead Neuroplastogen Candidate EB-003 - Investing News Network
Enveric Biosciences (ENVB) Achieves Key Milestone in Neuropsychi - GuruFocus
Enveric Biosciences Reports Financial Results and Provides Corporate Update for First Quarter 2026 - BioSpace
Enveric Biosciences Inc (ENVB) Stock Price, Quote, News & History - Benzinga
Enveric Biosciences (ENVB) affiliates report 158,732 warrants; Easton 161,232 - Stock Titan
Enveric (ENVB) Secures $13.9 Million in Private Placement Fundin - GuruFocus
Enveric (ENVB) Advances in Mental Health Therapeutics Developmen - GuruFocus
Enveric Biosciences Reports Q1 2026 Results, Advances Non-Hallucinogenic Antidepressant EB-003 Toward Clinical Trials - Minichart
Enveric Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Enveric Biosciences (NASDAQ: ENVB) posts Q1 2026 loss and flags going concern risk - Stock Titan
Enveric Biosciences (ENVB) advances EB-003 and boosts cash in Q1 2026 - Stock Titan
What's going on with Enveric Biosciences stock on Friday? - MSN
Enveric Biosciences Expands IP Portfolio with New U.S. Patent Issued for Methods of Treating Psychiatric Disorders - Investing News Network
Enveric highlights preclinical PTSD data amid rising focus on mental health therapies - MSN
Enveric Biosciences receives patent for psilocybin derivatives By Investing.com - Investing.com Canada
Enveric Biosciences (ENVB) Expands Patent Portfolio with New Psi - GuruFocus
Enveric Biosciences Stock Short Interest Rises to 45.7% - Moomoo
TradingKey - TradingKey
MSN Money - MSN
Enveric Biosciences Inc. (ENVB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ENVB Stock Price, Quote & Chart | ENVERIC BIOSCIENCES INC (NASDAQ:ENVB) - ChartMill
Enveric Biosciences Highlights Positive Results for EB-003 in PTSD Preclinical Model - Investing News Network
Enveric Biosciences IncReports positive preclinical results for EB-003 in PTSD model - marketscreener.com
Enveric Highlights Preclinical PTSD Data Amid Rising Focus On Mental Health TherapiesEnveric Bioscienc - Benzinga
Enveric Biosciences surges over 90%, other psychedelic stocks soar in Monday pre-market: What's going on? - MSN
Enveric Biosciences Corrects Reverse Stock Split Proxy Disclosure - TipRanks
Enveric Biosciences (ENVB) clarifies 1‑for‑15 max reverse split in 2026 proxy - Stock Titan
Enveric Biosciences | EFFECT: Others - Moomoo
Enveric Biosciences (NASDAQ: ENVB) files resale prospectus for 6.82M shares - Stock Titan
Lakewood-Amedex appoints Enveric CEO to board of directors - Investing.com UK
Lakewood-Amedex Biotherapeutics Appoints Joseph Tucker, Ph.D., to Board of Directors - Investing News Network
Lakewood-Amedex appoints Enveric CEO to board of directors By Investing.com - Investing.com Nigeria
Finanzdaten der Enveric Biosciences Inc-Aktie (ENVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.19%
0.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):